Trade Names:Prevacid NapraPAC 500- Tablets 15 mg lansoprazole/500 mg naproxen
Suppresses gastric acid secretion by blocking acid (proton) pump within gastric parietal cells.Naproxen
Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.
For reducing the risk of NSAID-associated gastric ulcers in patients with a history of documented gastric ulcers who need an NSAID for treatment of signs and symptoms of rheumatoid arthritis, osteoarthritis, and/or ankylosing spondylitis.
Treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; aspirin- or NSAID-related asthma, urticaria, or allergic-type reactions; hypersensitivity to any component of the product.
PO Lansoprazole 15 mg once daily and naproxen 500 mg twice daily. The naproxen dose and frequency may be adjusted to meet the patient's needs.
Store at 59° to 86°F. Protect from light and moisture.
Antihypertensive effect may be decreased by naproxen.Aspirin
Risk of serious GI complications, including bleeding, may be increased.Diuretics (eg, loop diuretics [eg, furosemide], thiazide diuretics [eg, hydrochlorothiazide])
Diuretic effect may be reduced.Drugs in which gastric pH is an important determinant of bioavailability (eg, ampicillin esters, digoxin, iron salts, ketoconazole)
Absorption may be altered by lansoprazole (eg, absorption of digoxin increased and ketoconazole decreased).Lithium
Lithium levels may be elevated, increasing the risk of toxicity.Probenecid
Naproxen plasma levels may be elevated and the t ½ may be prolonged.Sucralfate
Take lansoprazole at least 30 min prior to sucralfate.Theophylline
Cl may be increased slightly.
Naproxen may falsely increase urinary 17-ketosteroid values; may interfere with urinary assays for 5-hydroxy-indolacetic acid, decrease platelet aggregation, and prolong bleeding times.
Dizziness, drowsiness, headache, light-headedness, vertigo (1% to 10%); abnormal dreams, aseptic meningitis, cognitive dysfunction, depression, insomnia, malaise, speech disorder (postmarketing).
Edema, palpitations (1% to 10%); CHF, vasculitis (postmarketing).
Ecchymosis, pruritus, purpura, skin eruptions, sweating (1% to 10%); alopecia, erythema multiforme, photosensitivity (including cases resembling porphyria cutanea tarda), skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria (postmarketing).
Hearing disturbances, tinnitus, visual disturbances (1% to 10%); hearing impairment (postmarketing).
Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI ulcers, gross bleeding/perforation, heartburn, nausea, stomatitis, vomiting (1% to 10%); colitis, hematemesis, nonpeptic ulceration, pancreatitis, ulcerative stomatitis (postmarketing).
Glomerular nephritis, hematuria, interstitial nephritis, menstrual disorder, nephrotic syndrome, renal disease, renal failure, renal papillary necrosis, urinary retention (postmarketing).
Agranulocytosis, aplastic anemia, eosinophilia, granulocytopenia, hemolytic anemia, leukopenia, melena, neutropenia, pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura (postmarketing).
Abnormal LFTs, hepatotoxicity, jaundice (postmarketing).
Hyperglycemia, hyperkalemia, hypoglycemia (postmarketing).
Muscle weakness, myalgia, myositis (postmarketing).
Dyspnea (1% to 10%); eosinophilic pneumonitis (postmarketing).
Thirst (1% to 10%); anaphylactic reactions, angioneurotic edema, pyrexia (postmarketing).
NSAIDs may cause an increased risk of serious CV thrombotic events, MI, and stroke, which can be fatal. This risk may increase with length of therapy. Patients with CV disease or risk factors for CV disease may be at greater risk. Naproxen is contraindicated for the treatment of perioperative pain in the setting of CABG surgery. NSAIDs cause an increased risk of serious GI adverse reactions, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These reactions can occur any time during use and without warning symptoms. Elderly patients are at greater risk of serious GI reactions.
Determine hemoglobin values periodically in patients with an initial hemoglobin value of 10 g or less who receiving long-term therapy.
Category C . Avoid use in late pregnancy; may cause premature ductus arteriosus closure.
Excreted in breast milk.Lansoprazole
Safety and efficacy not established.
Naproxen-containing products are not recommended in patients with moderate to severe and severe renal function impairment (Ccr less than 30 mL/min).
Consider dosage adjustments for the naproxen component in elderly patients and patients with liver disease.
Use with caution in elderly patients or patients with fluid retention, hypertension, heart failure, or history of GI bleeding or ulcer disease.
Bleeding time may be prolonged as a result of inhibition of platelet aggregation.
Do not use naproxen sodium with other naproxen-containing drugs because they all will circulate as naproxen anion.
Onset of new hypertension or worsening of preexisting hypertension may occur, increasing the risk of CV events.
Because fever and inflammation may be reduced by naproxen, signs used in diagnosing complications of presumed noninfectious, noninflammatory painful conditions may be diminished.
Long-term administration may result in renal injury, including renal papillary necrosis.
Abdominal discomfort, acute renal failure, alterations in liver function, anaphylactoid reactions, apnea, coma, disorientation, dizziness, drowsiness, epigastric pain, GI bleeding, heartburn, hypertension, hypoprothrombinemia, indigestion, lethargy, metabolic acidosis, nausea, renal function impairment, respiratory depression, seizures, vomiting.
Copyright © 2009 Wolters Kluwer Health.